Latest News on MDXG

Financial News Based On Company


Advertisement
Advertisement

MiMedx Group Bets on Surgery Growth and Sanara Deal as Wound Care Struggles

https://www.tradingview.com/news/marketbeat:0521620cb094b:0-mimedx-group-bets-on-surgery-growth-and-sanara-deal-as-wound-care-struggles/
MiMedx Group is banking on its surgical business growth and the pending acquisition of Sanara MedTech to offset challenges in its wound care division, as stated by CFO Doug Rice. The company reported $62 million in Q3 net sales, with surgical products contributing two-thirds, and expects the Sanara deal to expand its surgical offerings and open up over $4 billion in new addressable markets. MiMedx anticipates becoming a $400 million revenue company with 20%+ adjusted EBITDA margins post-acquisition, while also navigating Medicare reimbursement changes that have impacted its wound care franchise.

MIMEDX to Participate in Upcoming Investor Conferences

https://www.manilatimes.net/2026/11/06/tmt-newswire/globenewswire/mimedx-to-participate-in-upcoming-investor-conferences/2464083
MiMedx Group, Inc. (MIMEDX) announced that its senior management will participate in two upcoming investor conferences: the Canaccord MedTech, Diagnostics and Digital Health & Services Forum on November 11, 2026, and the Craig-Hallum 17th Annual Alpha Select Conference on November 17, 2026. The company, a leader in wound care and surgical solutions, will hold one-on-one sessions and a presentation at these events. Investors interested in meeting with management are encouraged to contact their respective Canaccord or Craig-Hallum representatives.

MiMedx Group, Inc. (MDXG) stock price, news, quote and history

https://au.finance.yahoo.com/quote/MDXG/
MiMedx Group, Inc. (MDXG) stock experienced a slight gain of 0.91% at close on November 6th, trading at $3.3100. The company, which specializes in developing and distributing placental tissue allografts for healthcare, has seen significant declines over the past year, with a 54.84% drop, but analysts have set a 1-year target estimate of $7.00. Craig-Hallum maintained a "Buy" rating on August 27, 2026, and raised its price target to $8.

MIMEDX to Participate in Upcoming Investor Conferences

https://www.globenewswire.com/news-release/2026/11/06/3397484/0/en/mimedx-to-participate-in-upcoming-investor-conferences.html
MiMedx Group, Inc. (Nasdaq: MDXG) announced that its senior management will participate in two upcoming investor conferences: the Canaccord MedTech, Diagnostics and Digital Health & Services Forum on November 11, 2026, and the Craig-Hallum 17th Annual Alpha Select Conference on November 17, 2026. The company, a leader in wound care, burn, and surgical sectors, will hold 1:1 sessions and a presentation for interested investors.

MiMedx Group stock: Surgical growth offsets steep Wound decline

https://www.ad-hoc-news.de/boerse/news/nebenwerte/mimedx-group-stock-surgical-growth-offsets-steep-wound-decline/70460486
MiMedx Group (MIMEDX) reported Q3 2026 results showing a significant decline in net sales to $62 million due to Medicare reimbursement changes impacting its Wound business. Despite this, Surgical sales grew 9% year-over-year to $40 million, now comprising nearly two-thirds of total sales. The company achieved positive Adjusted EBITDA of $2.1 million and expects further improvement in Q4, while also progressing on the Sanara MedTech acquisition and regulatory matters.
Advertisement

MiMedx Group, Inc Stock 12‑Month Price Target Cut to $7, Implies 77% Upside

https://www.tradingview.com/news/tradingview:5079f069c041e:0-mimedx-group-inc-stock-12-month-price-target-cut-to-7-implies-77-upside/
Analysts have adjusted MiMedx Group, Inc's average 12-month price target down to $7 from $7.4, with individual forecasts ranging from $6 to $8 per share. This updated target suggests a potential upside of approximately 77% based on the Oct. 28 closing price. The consensus rating among the 5 covering analysts remains a "Buy."

MiMedx Group, Inc Stock 12‑Month Price Target Cut to $7, Implies 77% Upside

https://www.tradingview.com/news/tradingview:5079f069c041e:0-mimedx-group-inc-stock-12-month-price-target-cut-to-7-2-implies-82-upside/
The average 12-month price target for MiMedx Group, Inc (MDXG) stock has been revised down from $7.4 to $7 by five analysts, with individual forecasts ranging from $6 to $8 per share. This updated target suggests a potential upside of approximately 77% based on the Oct. 28 closing price. The consensus analyst rating remains a "Buy," with all five covering analysts recommending a purchase.

MIMEDX Announces $25 Million Patent License Agreement

https://www.manilatimes.net/2026/10/29/tmt-newswire/globenewswire/mimedx-announces-25-million-patent-license-agreement/2456606
MIMEDX Group, Inc. announced a $25 million patent license agreement with a wound care competitor, resolving allegations of infringement of MIMEDX’s patents. The agreement involves five annual installments of $5 million and grants the licensee a non-exclusive license to the covered patents. This deal highlights the strength of MIMEDX's intellectual property and provides significant recurring cash flow.

MiMedx Group, Inc. (MDXG) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/MDXG/
This article provides a comprehensive overview of MiMedx Group, Inc. (MDXG), including its stock price, historical data, and key financial metrics. It details the company's biotechnology focus, its product offerings in wound care and surgical applications, and recent earnings and analyst insights. The stock closed at $3.97, with an overnight price of $3.98, and reported Q3 2026 revenue of $62.28 million.

MIMEDX Announces $25 Million Patent License Agreement

https://www.manilatimes.net/2026/10/29/tmt-newswire/globenewswire/mimedx-announces-25-million-patent-license-agreement/2456606/amp
MiMedx Group, Inc. (Nasdaq: MDXG) has announced a $25 million patent license agreement with a wound care competitor, resolving allegations of patent infringement. The agreement includes five annual installments of $5 million and grants the licensee a non-exclusive license to MIMEDX's covered patents. This highlights the strength of MIMEDX's intellectual property and provides recurring cash flow for the company.
Advertisement

What MiMedx Group (MDXG) Said on Its Q3 Earnings Call

https://www.tradingview.com/news/marketbeat:a15dce39a094b:0-what-mimedx-group-mdxg-said-on-its-q3-earnings-call/
MiMedx Group (MDXG) reported Q3 net sales of $62 million, a 45% year-over-year decrease, primarily due to a significant decline in wound care revenue following Medicare reimbursement changes, partially offset by 9% growth in its surgical business. The company is strategically shifting towards surgical products and anticipates continued pressure in wound care. MiMedx also provided updates on its pending acquisition of Sanara MedTech, which is undergoing an extended FTC review, and shared its full-year 2026 standalone sales outlook of $250 million to $260 million.

MiMedx Group Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/10/62679054/mimedx-group-q3-2026-earnings-call-transcript
MiMedx Group reported Q3 2026 net sales of $62 million, with surgical revenue up 9% year-over-year and wound care center volume growing 7% sequentially, despite a 45% overall net sales decline. The company is actively pursuing the acquisition of Sanera MedTech, which is expected to significantly expand its surgical offerings and increase total revenue to nearly $400 million with double-digit growth and over 20% adjusted EBITDA margin. MiMedx also achieved a favorable court ruling regarding Axiofill's classification, settled a $25 million patent infringement case, and returned to positive adjusted EBITDA and cash flow for the quarter, with full-year net sales guidance set at $250 million to $260 million.

MIMEDX Announces Third Quarter 2026 Operating & Financial Results

https://www.globenewswire.com/news-release/2026/10/28/3390724/0/en/mimedx-announces-third-quarter-2026-operating-financial-results.html
MIMEDX reported Q3 2026 net sales of $62 million, a 45% decrease year-over-year, primarily due to Medicare reimbursement changes impacting Wound sales, despite surgical product sales increasing by 9%. The company achieved positive Adjusted EBITDA for the quarter and is progressing with its acquisition of Sanara MedTech, while also announcing a favorable federal court ruling regarding AXIOFILL's regulatory classification and a $25 million patent license agreement. MIMEDX projects 2026 net sales between $250 million and $260 million and expects continued double-digit annual net sales growth long-term.

Wound sales fall 71% at MiMedx (MDXG) as Medicare reimbursement changes weigh on Q3 results.

https://www.stocktitan.net/sec-filings/MDXG/8-k-mimedx-group-inc-reports-material-event-76a342a7fd04.html
MiMedx Group, Inc. reported a 45% year-over-year decline in net sales to $62.3 million for Q3 2026, primarily due to a 71% drop in Wound sales attributed to Medicare reimbursement changes. Despite a net loss of $8.7 million, the company achieved positive Adjusted EBITDA of $2.1 million and expects 2026 net sales between $250 million and $260 million. MiMedx also announced a $25 million patent license agreement and a favorable federal court ruling regarding its AXIOFILL product's regulatory classification.

MIMEDX Announces $25 Million Patent License Agreement

https://www.globenewswire.com/news-release/2026/10/28/3390715/0/en/mimedx-announces-25-million-patent-license-agreement.html
MiMedx Group, Inc. (Nasdaq: MDXG) has announced a patent license agreement with a wound care competitor, resolving infringement allegations. Under the agreement, MIMEDX will receive $25 million in five annual installments of $5 million and has granted a non-exclusive license to the covered patents. This agreement highlights the strength of MIMEDX's intellectual property portfolio and provides significant recurring cash flow.
Advertisement

MiMedx Group, Inc Estimates – NASDAQ:MDXG

https://www.tradingview.com/symbols/NASDAQ-MDXG/financials-estimates/
This article provides access to the financial actuals and analyst estimates for MiMedx Group, Inc. (NASDAQ: MDXG) on TradingView. Users can explore reported financial data and analyst estimates across various financial statements and visualize trends over time. The platform allows comparison of actual results with average, high, and low estimates.

MiMedx stock: FTC requests more merger documents. Why it matters for MiMedx stock?

https://www.ad-hoc-news.de/boerse/news/nebenwerte/mimedx-stock-ftc-requests-more-merger-documents-why-it-matters-for-mimedx-stock/70395985
The Federal Trade Commission has issued a Second Request to MiMedx Group regarding its proposed merger with Sanara MedTech, extending the waiting period by 30 days. This regulatory hurdle comes shortly before MiMedx is set to report its third-quarter 2026 financial results on October 28, 2026, adding an execution milestone to the acquisition timeline. The merger is intended to expand MiMedx's surgical portfolio, and its completion is now contingent on the resolution of the FTC review and other closing conditions.

MiMedx Group Insider Lowered Holding By 71% During Last Year

https://www.moomoo.com/news/post/1001590240/mimedx-group-insider-lowered-holding-by-71-during-last-year
The article reports that an insider at MiMedx Group significantly reduced their stake in the company over the last year, decreasing their holding by 71%. This information is relevant for investors tracking insider sentiment and potential implications for the company's stock.

Sanara MedTech merger faces extended FTC review

https://www.theglobeandmail.com/investing/markets/stocks/SMTI-Q/pressreleases/8140970/sanara-medtech-merger-faces-extended-ftc-review/
Sanara MedTech's pending merger with MiMedx Group is facing an extended review by the Federal Trade Commission (FTC). Both companies received a Second Request for additional information on October 15, 2026, which prolongs the Hart-Scott-Rodino waiting period and delays the deal's closing. This regulatory scrutiny introduces uncertainty regarding the transaction's completion timing and integration plans.

MiMedx-Sanara Merger Faces Fresh Regulatory Obstacle – SMTI Stock Falls Below This Key Support Level For The First Time In 4 Months

https://finance.yahoo.com/healthcare/articles/mimedx-sanara-merger-faces-fresh-170012008.html
The proposed merger between MiMedx Group (MDXG) and Sanara MedTech (SMTI) has hit a regulatory snag as the Federal Trade Commission (FTC) issued a Second Request for additional documents, potentially delaying the deal beyond its year-end target. This news caused both SMTI and MDXG stocks to fall, with SMTI dropping below its 50-day moving average for the first time in months. Despite the delay, the combined entity aims for over $400 million in full-year 2027 revenue and significant cost savings.
Advertisement

FTC Second Requests Extend Review of Sanara-MiMedx Merger

https://www.tokenpost.com/news/regulation/33687
The Federal Trade Commission (FTC) has issued Second Requests to Sanara MedTech Inc. and MiMedx Group Inc., extending the federal review of their proposed merger. This action, taken on October 15, seeks additional information under the Hart-Scott-Rodino Act, delaying the deal's potential closing. Sanara shareholders approved the merger on September 30, and the companies are targeting a year-end 2026 closing, pending regulatory approval.

Form 425 Sanara MedTech Inc. Filed by: MIMEDX GROUP, INC.

https://www.streetinsider.com/SEC+Filings/Form+425+Sanara+MedTech+Inc.+Filed+by%3A+MIMEDX+GROUP%2C+INC./27196269.html
MiMedx Group, Inc. has filed a Form 425 regarding its proposed merger with Sanara MedTech Inc. The filing indicates that both companies received a Second Request from the Federal Trade Commission (FTC) in connection with the FTC's review of the merger, which extends the waiting period under the HSR Act. The completion of the merger remains subject to regulatory approvals and other closing conditions.

MiMedx schedules October 28 results. Analysts set a USD 8.57 target for MiMedx stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/mimedx-schedules-october-28-results-analysts-set-a-usd-8-57-target-for-mimedx-stock/70334592
MiMedx has scheduled its third-quarter results webcast for October 28, 2026, at 4:30 p.m. Eastern Time. The company's second-quarter revenue of $64.36 million exceeded estimates, and analysts have set an average 12-month price target of $8.57 with a "Moderate Buy" consensus. Investors are anticipating the upcoming report to understand if surgical demand is balancing other wound-care activities and how revenue growth impacts earnings.

MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026

https://www.globenewswire.com/news-release/2026/10/14/3381120/0/en/mimedx-to-host-third-quarter-2026-operating-and-financial-results-conference-call-on-october-28-2026.html
MIMEDX Group, Inc. (Nasdaq: MDXG) announced it will report its third-quarter 2026 operating and financial results after market close on Wednesday, October 28, 2026. The company's senior management team will host a webcast and conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. A replay of the webcast will be available on the MIMEDX website for approximately 30 days.

MiMedx Group stock gained 1.54 percent on October 6

https://www.ad-hoc-news.de/boerse/news/nebenwerte/mimedx-group-stock-gained-1-54-percent-on-october-6/70248636
MiMedx Group (MDXG) stock gained 1.54 percent on October 6, closing at USD 4.62 on Nasdaq. This increase followed a "Moderate Buy" consensus from seven analysts, who set an average 12-month price target of USD 8.57, representing an 85.5 percent upside. The company also reported Q2 revenue of USD 64.36 million, exceeding estimates, while its EPS loss matched expectations.
Advertisement

Sanara MedTech Shareholders Approve Merger with MiMedx

https://www.theglobeandmail.com/investing/markets/stocks/SMTI-Q/pressreleases/4925324/sanara-medtech-shareholders-approve-merger-with-mimedx/
Sanara MedTech shareholders have approved a merger agreement under which it will become a wholly owned subsidiary of MiMedx Group Inc. The merger still requires regulatory review under the Hart-Scott-Rodino Act and the satisfaction of other closing conditions. Analysts currently rate SMTI as a Hold with a $35.00 price target, noting weak financial quality despite strong revenue trends, though the acquisition provides a positive catalyst.

What Does the AXIOFILL Court Ruling Mean for MiMedx (NASDAQ:MDXG)?

https://kalkinemedia.com/us/stocks/healthcare/what-does-the-axiofill-court-ruling-mean-for-mimedx-nasdaqmdxg
A federal court recently vacated FDA determinations regarding the regulatory classification of MiMedx's product, AXIOFILL. This ruling removes the FDA's previous classification decisions, creating a clearer path for the company's execution and disclosure. The article emphasizes the importance of this development for MiMedx, particularly within the broader context of the evolving healthcare market, investor expectations, and regulatory landscape.

MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter

https://investingnews.com/mimedx-announces-favorable-federal-court-ruling-in-axiofill-r-regulatory-classification-matter/
MIMEDX announced a favorable federal court ruling regarding the regulatory classification of its product, AXIOFILL. The U.S. District Court for the Northern District of Georgia vacated FDA determinations that AXIOFILL is not minimally manipulated and should be classified as a biological product, remanding the matters for further consideration. This ruling challenges the FDA's interpretation of minimal manipulation and its inconsistent classification of AXIOFILL compared to similar products.

MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter

https://www.globenewswire.com/news-release/2026/09/23/3367829/0/en/mimedx-announces-favorable-federal-court-ruling-in-axiofill-regulatory-classification-matter.html
MIMEDX Group, Inc. announced a favorable federal court ruling regarding the regulatory classification of its product, AXIOFILL. The court vacated the FDA's determinations that AXIOFILL is not minimally manipulated and should be classified as a biological product, remanding the matters for further consideration. MIMEDX CEO Joseph H. Capper expressed satisfaction with the ruling, stating it addresses central issues and affirms the company's belief that AXIOFILL meets the requirements for classification as a Section 361 HCT/P.

MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter

https://finance.yahoo.com/healthcare/articles/mimedx-announces-favorable-federal-court-200100057.html
MIMEDX announced a favorable federal court ruling that vacated the FDA's determinations regarding the regulatory classification of its AXIOFILL product. The court found that the FDA incorrectly interpreted its minimal-manipulation regulation and did not adequately explain the disparate classification of AXIOFILL compared to similar products. This ruling remands the matter to the FDA for further consideration, with MIMEDX expressing confidence that AXIOFILL meets the requirements for Section 361 HCT/P classification.
Advertisement

U.S. District Court Orders FDA to Reclassify MiMedx Wound Powder as Device

https://www.lawxyai.com/news/u-s-district-court-orders-fda-to-reclassify-mimedx-wound-powder-as-device
A U.S. District Court in Georgia has ordered the FDA to reclassify MiMedx’s wound-care powder from a biological product to a device, stating the FDA's initial designation was arbitrary. This ruling means manufacturers of similar wound-care powders will now follow device regulatory requirements, simplifying the approval process. The decision emphasizes that the FDA must apply a consistent and reasoned analysis when distinguishing between devices and biologics.

MiMedx Group, Inc (MDXG) Stock Analysis: Exploring a 53.85% Potential Upside in Biotechnology

https://www.directorstalkinterviews.com/mimedx-group-inc-mdxg-stock-analysis-exploring-a-53-85-potential-upside-in-biotechnology/4121263478
MiMedx Group, Inc. (MDXG), a biotechnology company specializing in placental tissue allografts, shows a potential upside of 53.85% according to analysts. Despite a revenue growth decline, the company maintains a positive EPS and robust free cash flow, with strong analyst ratings and a target price of $7.40. Technical indicators suggest the stock may be nearing an oversold territory, presenting an opportune entry point for investors.

MiMedx Group stock steadies as investors look to upcoming catalysts

https://www.ad-hoc-news.de/boerse/news/nebenwerte/mimedx-group-stock-steadies-as-investors-look-to-upcoming-catalysts/70135684
MiMedx Group stock is trading near recent levels on Nasdaq, with investors analyzing the latest revenue and earnings reports. The company's financial performance, guidance for the current fiscal year, and balance sheet metrics are key factors influencing market sentiment. Investors are also comparing the current stock price with its 52-week high and low to assess its position within its recent trading range.

MIMEDX GROUP, INC. SEC Filing (Sep 8, 2026)

https://www.stocktitan.net/sec-filings/MDXG/effect-mimedx-group-inc-sec-filing-8e626408e27e.html
This article reports on an SEC filing (Form EFFECT) by MIMEDX GROUP, INC. (MDXG) with an effectiveness date of September 4, 2026, at 11:00 A.M. The filing was accepted by SEC EDGAR on September 8, 2026. The article also provides recent news and other SEC filings related to MIMEDX GROUP, INC.

MIMEDX to Participate in Upcoming Investor Conferences

https://www.globenewswire.com/news-release/2026/09/08/3357558/0/en/mimedx-to-participate-in-upcoming-investor-conferences.html
MiMedx Group, Inc. (Nasdaq: MDXG) announced that its senior management will participate in the Cantor Global Healthcare Conference on September 9, 2026, and the Lake Street BIG10 Best Ideas Growth Conference on September 10, 2026, both in New York, NY. These participations will involve one-on-one sessions with investors. MIMEDX is a leader in wound care, burn, and surgical healthcare products.
Advertisement

MIMEDX to Participate in Upcoming Investor Conferences

https://finance.yahoo.com/healthcare/articles/mimedx-participate-upcoming-investor-conferences-120000389.html
MiMedx Group, Inc. (Nasdaq: MDXG) announced that its senior management will participate in two upcoming investor conferences: the Cantor Global Healthcare Conference on September 9, 2026, and the Lake Street BIG10 Best Ideas Growth Conference on September 10, 2026. Both events will feature 1:1 sessions with investors. MiMedx is a leader in healing solutions, focusing on wound care, burn, and surgical sectors.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

https://www.easternprogress.com/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-mimedx-group-inc/article_b956aac0-f601-5af6-a253-86faa130513d.html
Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. (NASDAQ: MDXG) following a significant drop in its stock price. The investigation concerns potential securities fraud or unlawful business practices by the company's officers and directors. This follows MiMedx reporting Q1 2026 financial results that missed consensus estimates for both earnings per share and revenue, attributing the decline to new Medicare reimbursement policies in advanced wound care.

Sanara MedTech (SMTI) agrees to MiMedx takeover, targeting year-end close

https://www.stocktitan.net/sec-filings/SMTI/425-sanara-med-tech-inc-business-combination-communication-56f938016d53.html
Sanara MedTech Inc. (SMTI) has entered into a definitive agreement to be acquired by MiMedx Group, Inc., aiming to create a leading regenerative medicine company. The transaction, which is subject to regulatory and stockholder approvals, is expected to close by the end of the year. Both companies will operate independently until closing, with existing distributor agreements remaining unchanged.

MiMedx Group (SMTI partner) clarifies Sanara merger fees and $33 cash-plus-stock deal

https://www.stocktitan.net/sec-filings/SMTI/425-sanara-med-tech-inc-business-combination-communication-84a6064e55a4.html
MiMedx Group has clarified the termination fees for its merger with Sanara MedTech Inc., stating Sanara would owe $9.66 million in specific cases and MiMedx $22.54 million if it fails to close. The deal offers Sanara shareholders $33.00 cash plus 0.4735 shares of MiMedx common stock per share, and MiMedx has secured a $300 million loan to finance the acquisition. The transaction is subject to Sanara stockholder and antitrust approvals, with a voting agreement covering 38.9% of Sanara's voting power already in place.

Sanara MedTech (SMTI) sets $33 cash plus MiMedx stock merger terms and corrects fees

https://www.stocktitan.net/sec-filings/SMTI/425-sanara-med-tech-inc-business-combination-communication-24e6f0082a4d.html
Sanara MedTech Inc. has confirmed the terms of its merger with MiMedx Group, Inc., where each Sanara share will convert into $33.00 in cash and 0.4735 shares of MiMedx common stock, valued at $2.00 per share. This amendment also corrects previously misstated termination fees, with Sanara owing $9,660,336.00 to MiMedx in specific scenarios and MiMedx owing Sanara $22,540,785.00 if it fails to close the deal. The merger is supported by a voting agreement covering approximately 38.9% of Sanara's voting power and is subject to regulatory and stockholder approvals with an outside date of July 29, 2027.
Advertisement

MiMedx Group, Inc Revenue Breakdown – NASDAQ:MDXG

https://www.tradingview.com/symbols/NASDAQ-MDXG/financials-segments/
This article provides a revenue breakdown for MiMedx Group, Inc (NASDAQ: MDXG). Last year, the company generated $418.63 million USD in total revenue, with its Wound segment being the top performer, contributing $276.33 million USD. The United States was the greatest regional contributor to revenue, accounting for the entire $418.63 million USD.

MiMedx Group Inc (MDXG) Stock News Today

https://www.tradingkey.com/markets/stocks/mdxg/news
This article from TradingKey provides current stock information for MiMedx Group Inc (MDXG), including its stock price, market cap, and P/E ratio. It notes that more news regarding MDXG's earnings, analyst ratings, and key developments will be available soon. The page serves as a hub for financial data and future news updates for the company.

MiMedx Group's (NASDAQ:MDXG) Soft Earnings Are Actually Better Than They Appear

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdxg/mimedx-group/news/mimedx-groups-nasdaqmdxg-soft-earnings-are-actually-better-t
MiMedx Group's recent earnings might seem weak, but a deeper analysis reveals a stronger financial position than initially perceived. The company's accrual ratio of -0.36 indicates that its free cash flow significantly exceeded its reported statutory profit, suggesting an understatement of its true earnings potential. Additionally, MiMedx Group is experiencing strong EPS growth, further supporting a more optimistic outlook.

MiMedx Group Inc (MDXG) Earnings Forecast: Future EPS & Revenue Growth Estimates

https://www.tradingkey.com/markets/stocks/mdxg/forecast
The article provides an earnings forecast for MiMedx Group Inc (MDXG), highlighting its current earnings forecast score of 8.00 and an average analyst price target of $12.00. Based on 5 analysts, the stock has a "Buy" rating with a potential upside of 61.29%. Key financial expectations include a forecasted revenue of $70.25M for the next quarter and an expected EPS of -$0.02.

Lazard Asset Management LLC Sells 264,718 Shares of MiMedx Group, Inc $MDXG

https://www.marketbeat.com/instant-alerts/filing-lazard-asset-management-llc-sells-264718-shares-of-mimedx-group-inc-mdxg-2026-08-04/
Lazard Asset Management LLC significantly reduced its stake in MiMedx Group, Inc. (MDXG) by selling 264,718 shares, a 38.6% decrease, though it still holds 420,706 shares. Despite this sale, other major institutional investors like Vanguard, State Street, Paradigm Capital, and Renaissance Technologies increased their holdings in the biopharmaceutical company. MiMedx Group's stock recently rose 3.4%, and the company met EPS estimates while exceeding revenue expectations, maintaining a "Moderate Buy" consensus rating from analysts.
Advertisement

MiMedx Group Number of Employees 2026 | Employee Count & Headcount Data

https://www.reveliolabs.com/companies/mimedx-group/employees
MiMedx Group (NASDAQ: MDXG) had 799 employees globally as of March 2026, representing a 1.0% decline since 2023. The company is actively hiring, with 40 active job postings in 2026, though new postings are slowing. The workforce is primarily concentrated in the United States, and the largest functional groups are Finance and Operations, and Engineering.

Renaissance Technologies LLC Has $11.93 Million Stake in MiMedx Group, Inc $MDXG

https://www.marketbeat.com/instant-alerts/filing-renaissance-technologies-llc-has-1193-million-stake-in-mimedx-group-inc-mdxg-2026-08-02/
Renaissance Technologies LLC increased its stake in MiMedx Group, Inc (MDXG) by 22.4% in the first quarter, now holding 3.02 million shares valued at $11.93 million, representing 2.03% of the company. Despite some recent analyst price target reductions and downgrades, the stock maintains a "Moderate Buy" consensus rating with a target price of $8.50. MiMedx reported Q2 revenue of $64.36 million and an EPS of negative $0.05, matching analyst expectations.

MIMEDX to Acquire Sanara MedTech

https://orthotw.com/2026/07/mimedx-to-acquire-sanara-medtech
MIMEDX Group, Inc. announced its definitive merger agreement to acquire Sanara MedTech Inc. in a cash and stock transaction valued at approximately $350 million. This acquisition aims to significantly expand MIMEDX’s surgical footprint, nearly doubling its surgical revenue, and creating a leading regenerative medicine company. The combined entity is expected to achieve over $400 million in total revenue by 2027 with an Adjusted EBITDA margin exceeding 20%, driven by anticipated cost synergies and an expanded product portfolio.

Q2 2026 MiMedx Group Inc Earnings Call and to Acquire Sanara MedTech Transcript

https://www.gurufocus.com/stock/MDXG/transcripts/8988731
MiMedx Group Inc (MDXG) reported strong sequential revenue growth in Q2 2026, with surgical business growing 15% year-over-year. The company announced its acquisition of Sanara MedTech, which is expected to be immediately accretive and transformational, aiming for over $400 million in revenue and 20%+ adjusted EBITDA margin by 2027 for the combined entity. Despite these positive developments, net sales decreased 35% year-over-year due to Medicare reimbursement changes, and the wound care market continues to face challenges.

Sanara MedTech (SMTI) plans business combination with MiMedx Group to build regenerative leader

https://www.stocktitan.net/sec-filings/SMTI/425-sanara-med-tech-inc-business-combination-communication-3298be3a0adb.html
Sanara MedTech (SMTI) has announced a proposed business combination with MiMedx Group, Inc., aiming to establish a leading regenerative medicine company focused on surgical and wound care applications. The transaction is expected to close by year-end, pending regulatory and shareholder approvals. Until then, both companies will operate independently.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement